Copyright
©The Author(s) 2017.
World J Hepatol. Feb 8, 2017; 9(4): 217-223
Published online Feb 8, 2017. doi: 10.4254/wjh.v9.i4.217
Published online Feb 8, 2017. doi: 10.4254/wjh.v9.i4.217
Table 2 Sustained viral response rates
| A5294 participants (n = 257) | % SVR12 |
| Treatment naïve (n = 135) | 35.6 |
| Non-cirrhotic (n = 117) | 36.8 |
| Cirrhotic (n = 18) | 27.8 |
| Treatment experienced (n = 122) | 30.3 |
| Non-cirrhotic (n = 84) | 32.1 |
| Cirrhotic (n = 38) | 26.3 |
- Citation: Sherman KE, Kang M, Sterling R, Umbleja T, Marks K, Kiser JJ, Alston-Smith B, Greaves W, Butt AA, the ACTG 5294 BIRTH Study Team. Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection. World J Hepatol 2017; 9(4): 217-223
- URL: https://www.wjgnet.com/1948-5182/full/v9/i4/217.htm
- DOI: https://dx.doi.org/10.4254/wjh.v9.i4.217